Can Fite Biopharma Stock Today
| CANF Stock | USD 1.63 0.39 19.31% |
PerformanceOK
| Odds Of DistressBelow Average
|
Can Fite is trading at 1.63 as of the 20th of March 2025. This is a 19.31% down since the beginning of the trading day. The stock's lowest day price was 1.59. Can Fite has about a 40 percent probability of financial distress in the next few years of operation but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of November 2012 | Category Healthcare | Classification Health Care |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. The company has 6.1 M outstanding shares of which 255.92 K shares are currently shorted by private and institutional investors with about 2.39 trading days to cover. More on Can Fite Biopharma
Moving against Can Stock
Can Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, Director | Pnina Fishman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCan Fite can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Can Fite's financial leverage. It provides some insight into what part of Can Fite's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Can Fite Biopharma (CANF) is traded on NYSE MKT Exchange in USA. It is located in 26 Ben Gurion Street, Ramat Gan, Israel, 5257346 and employs 8 people. Can Fite is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.31 M. Can Fite Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.1 M outstanding shares of which 255.92 K shares are currently shorted by private and institutional investors with about 2.39 trading days to cover.
Can Fite Biopharma currently holds about 12.77 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Check Can Fite Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Can Fite Biopharma is $12.31 Million. Almost 98.49 percent of Can Fite outstanding shares are held by general public with 1.51 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Can Ownership Details
Can Fite Historical Income Statement
Can Stock Against Markets
Can Fite Corporate Management
| Motti Farbstein | Chief Operating and Financial Officer and Principal Accounting Officer | Profile | |
| Sari Fishman | Vice Development | Profile | |
| Ilan Cohn | CoFounder Chairman | Profile | |
| FACP FACR | Clinical Advisor | Profile | |
| MD FACP | Member Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.